Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Authors:
- Jesus M. BanalesJesus M. Banales
- Pedro M. RodriguesPRPedro M. Rodrigues
- Silvia AffòSASilvia Affò
- Jesper B. AndersenJAJesper B. Andersen
- Patricia AspichuetaPAPatricia Aspichueta
- Luke BoulterLBLuke Boulter
- John BridgewaterJBJohn Bridgewater
- Diego F. CalvisiDCDiego F. Calvisi
- Guido CarpinoGCGuido Carpino
- Cédric CoulouarnCédric Coulouarn
Top Cited Papers
Open Access
- 10 December 2025
- journal article
- review article
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 23 (1) , 65-96
Abstract
Cholangiocarcinoma (CCA) is a cancer that originates within the bile ducts. Traditionally considered to be a rare neoplasm, increased awareness of CCA alongside advancements in diagnosis and the rising prevalence of certain risk factors have contributed to a global increase in incidence and mortality. CCAs are highly heterogeneous from the clinical, histomorphological and molecular perspectives but commonly share a poor prognosis. These tumours usually develop and progress silently; by the time they are detected, it is often too late for curative surgical intervention. In such cases, current therapeutic approaches offer modest survival improvements and are generally considered palliative. Although well-known risk factors predispose individuals to developing CCA, the majority of cases are considered sporadic, occurring without any identifiable underlying condition. Over the past decade, substantial collaborative efforts have been made to improve our understanding of the aetiopathogenesis of these tumours, aiming to identify novel biomarkers and therapeutic targets to develop more effective treatments. The ultimate goal is to improve patient outcomes and overall well-being. However, there are significant gaps in our understanding of the molecular mechanisms that drive cholangiocarcinogenesis. In this international Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we provide a critical overview of the latest advancements in the field of CCA. We highlight the key aspects of CCA aetiopathogenesis and clinical management and provide insights into promising new treatments. Finally, we provide a set of consensus recommendations and future research priorities for CCA based on a Delphi panel questionnaire involving international experts.Keywords
This publication has 381 references indexed in Scilit:
- KRAS Allelic Variants in Biliary Tract CancersJAMA Network Open, 2024
- Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019JAMA Network Open, 2023
- Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract CancerJAMA Oncology, 2023
- Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic CholangiocarcinomaJAMA Surgery, 2022
- Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic CholangiocarcinomaJAMA Surgery, 2021
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic CholangiocarcinomaJAMA Oncology, 2020
- Association Between Aspirin Use and Biliary Tract Cancer SurvivalJAMA Oncology, 2019
- O‐GlcNAc‐induced nuclear translocation of hnRNP‐K is associated with progression and metastasis of cholangiocarcinomaMolecular Oncology, 2018
- Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinomaBritish Journal of Surgery, 2017